Kalevi Kurkijarvi Sells 4,000 Shares of FibroGen (FGEN) Stock

FibroGen (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock in a transaction on Thursday, April 19th. The stock was sold at an average price of $47.69, for a total value of $190,760.00. Following the completion of the sale, the director now directly owns 24,000 shares of the company’s stock, valued at approximately $1,144,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kalevi Kurkijarvi also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, February 15th, Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock. The stock was sold at an average price of $55.69, for a total value of $334,140.00.

NASDAQ FGEN opened at $46.40 on Friday. The company has a current ratio of 9.70, a quick ratio of 9.70 and a debt-to-equity ratio of 0.17. FibroGen has a fifty-two week low of $25.35 and a fifty-two week high of $63.00.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. The company had revenue of $42.51 million for the quarter, compared to the consensus estimate of $45.37 million. sell-side analysts expect that FibroGen will post -1.35 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. lifted its position in shares of FibroGen by 22.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 333,660 shares of the biopharmaceutical company’s stock valued at $17,951,000 after acquiring an additional 61,086 shares in the last quarter. Legal & General Group Plc lifted its position in shares of FibroGen by 31.1% in the third quarter. Legal & General Group Plc now owns 27,967 shares of the biopharmaceutical company’s stock valued at $1,500,000 after acquiring an additional 6,634 shares in the last quarter. Carillon Tower Advisers Inc. purchased a new position in shares of FibroGen in the fourth quarter valued at about $282,486,000. Jennison Associates LLC lifted its position in shares of FibroGen by 23.1% in the fourth quarter. Jennison Associates LLC now owns 276,914 shares of the biopharmaceutical company’s stock valued at $13,126,000 after acquiring an additional 51,914 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of FibroGen by 1,058.4% in the fourth quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock valued at $36,813,000 after acquiring an additional 709,598 shares in the last quarter. Institutional investors and hedge funds own 61.39% of the company’s stock.

Several equities analysts recently weighed in on the company. Mizuho reiterated a “hold” rating and set a $61.00 target price on shares of FibroGen in a research report on Thursday, March 29th. Zacks Investment Research downgraded FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. TheStreet upgraded FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Finally, Leerink Swann reiterated an “outperform” rating and set a $88.00 target price (up from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $66.67.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://weekherald.com/2018/04/22/kalevi-kurkijarvi-sells-4000-shares-of-fibrogen-fgen-stock.html.

FibroGen Company Profile

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply